Home > Boards > US Listed > Medical - Drugs > GlaxoSmithKline (GSK)

GlaxoSmithKline (NYSE: GSK) wants binding bids by next

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Stock Guy777 Member Profile
 
Followed By 66
Posts 3,750
Boards Moderated 0
Alias Born 02/20/13
160x600 placeholder
Pound Surges On Report Of Possible Draft Brexit Deal Dow Jones News - 10/15/2019 11:58:00 AM
Brexit Hopes Sends British Pound To Highest Level Of Johnson Administration As U.K. Banks Soar Dow Jones News - 10/12/2019 9:44:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/11/2019 1:32:13 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/11/2019 12:41:17 PM
Brexit Hopes Sends British Pound To Highest Level Of Johnson Administration As U.K. Banks Soar Dow Jones News - 10/11/2019 11:55:00 AM
Brexit Hopes Sends British Pound To Highest Level Of Johnson Administration As U.K. Banks Soar Dow Jones News - 10/11/2019 10:34:00 AM
Brexit Hopes Fuel Fresh Rally For The British Pound To Highest Level Of Johnson Administration Dow Jones News - 10/11/2019 9:10:00 AM
Brexit Hopes Fuel Fresh Rally For The British Pound To Highest Level Of Johnson Administration Dow Jones News - 10/11/2019 7:56:00 AM
Brexit Hopes Fuel Fresh Rally For The British Pound Dow Jones News - 10/11/2019 7:48:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/10/2019 12:30:05 PM
Glaxo Links Up with US Biotech to Target Solid Tumors with Cell Therapy Dow Jones News - 10/8/2019 11:26:00 AM
GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma Business Wire - 10/2/2019 9:08:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/1/2019 1:50:42 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/1/2019 11:39:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/30/2019 11:11:15 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/30/2019 7:01:33 AM
GlaxoSmithKline Says Ovarian Cancer Study Validates Tesaro Acquisition -- WSJ Dow Jones News - 9/30/2019 3:02:00 AM
GlaxoSmithKline Says Ovarian Cancer Study Validates Tesaro Acquisition Dow Jones News - 9/28/2019 3:59:00 PM
GlaxoSmithKline Says Ovarian Cancer Study Validates Tesaro Acquisition Dow Jones News - 9/28/2019 11:07:00 AM
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardles... PR Newswire (Canada) - 9/28/2019 10:31:00 AM
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardles... PR Newswire (US) - 9/28/2019 10:31:00 AM
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardles... PR Newswire (US) - 9/28/2019 10:31:00 AM
GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with p... PR Newswire (US) - 9/28/2019 2:53:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/26/2019 1:48:35 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/17/2019 1:26:31 PM
Stock Guy777   Tuesday, 10/14/14 03:13:54 PM
Re: None
Post # of 140 
GlaxoSmithKline (NYSE: GSK) wants binding bids by next month for older drugs worth $3 billion, according to reports from Reuters. Potential bidders include KKR, India's Lupin and Denmark's Lundbeck, the report said.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist